JP2014518883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518883A5 JP2014518883A5 JP2014512833A JP2014512833A JP2014518883A5 JP 2014518883 A5 JP2014518883 A5 JP 2014518883A5 JP 2014512833 A JP2014512833 A JP 2014512833A JP 2014512833 A JP2014512833 A JP 2014512833A JP 2014518883 A5 JP2014518883 A5 JP 2014518883A5
- Authority
- JP
- Japan
- Prior art keywords
- tl1a
- monoclonal antibody
- clone
- agent
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161488671P | 2011-05-20 | 2011-05-20 | |
| US61/488,671 | 2011-05-20 | ||
| PCT/US2012/028926 WO2012161856A1 (en) | 2011-05-20 | 2012-03-13 | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014518883A JP2014518883A (ja) | 2014-08-07 |
| JP2014518883A5 true JP2014518883A5 (enExample) | 2015-03-19 |
Family
ID=47217582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512833A Withdrawn JP2014518883A (ja) | 2011-05-20 | 2012-03-13 | Ｔ細胞媒介疾病の病態を改善させるためのｔｌ１ａ−ｄｒ３相互作用の遮断及びその抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9068003B2 (enExample) |
| EP (1) | EP2709664A4 (enExample) |
| JP (1) | JP2014518883A (enExample) |
| KR (1) | KR20140104344A (enExample) |
| AU (1) | AU2012259312A1 (enExample) |
| CA (1) | CA2836898A1 (enExample) |
| MX (1) | MX2013013329A (enExample) |
| WO (1) | WO2012161856A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005018571A2 (en) * | 2003-08-20 | 2005-03-03 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
| AU2006284922B2 (en) | 2005-08-30 | 2012-01-19 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins |
| US9896511B2 (en) | 2007-01-10 | 2018-02-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies |
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| SG10201502330TA (en) | 2009-08-03 | 2015-05-28 | Univ Miami | Method for in vivo expansion of t regulatory cells |
| US8766034B2 (en) | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
| KR101982899B1 (ko) | 2011-09-30 | 2019-05-27 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | ＴＬ1ａ에 대한 항체 및 그의 용도 |
| WO2014106602A1 (en) * | 2013-01-02 | 2014-07-10 | Glenmark Pharmaceuticals S.A. | Antibodies that bind to tl1a and their uses |
| US20140193410A1 (en) | 2013-01-09 | 2014-07-10 | University Of Miami | Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein |
| KR20230109779A (ko) | 2013-03-27 | 2023-07-20 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전 |
| ES2894963T3 (es) * | 2013-05-17 | 2022-02-16 | Cedars Sinai Medical Center | Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn |
| WO2014186665A2 (en) * | 2013-05-17 | 2014-11-20 | Cedars-Sinai Medical Center | Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis |
| EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| MX2016002879A (es) * | 2013-09-06 | 2016-08-17 | Cedars Sinai Medical Center | Sistemas, dispositivos y metodos para la terapia anti-tl1a. |
| US9683998B2 (en) * | 2013-11-13 | 2017-06-20 | Pfizer Inc. | Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof |
| CN106536548A (zh) * | 2014-04-28 | 2017-03-22 | 国家生物技术研究所公司 | Dr3变体及其用途 |
| EP3730188B1 (en) | 2015-08-21 | 2024-07-31 | The Children's Hospital of Philadelphia | Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| US20180319889A1 (en) * | 2015-11-02 | 2018-11-08 | La Jolla Institute For Allergy & Immunology | Method and medicament for treating airway and/or lung diseases |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| KR20240095481A (ko) | 2016-03-17 | 2024-06-25 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
| EP3458466B1 (en) | 2016-05-20 | 2024-08-07 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease based on genes |
| KR20190082815A (ko) * | 2016-10-26 | 2019-07-10 | 세다르스-신나이 메디칼 센터 | 중화 항-tl1a 단일 클론 항체 |
| CN112585165B8 (zh) | 2018-04-25 | 2025-02-14 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| WO2020113116A1 (en) * | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Methods of stratifying and treating a sub-population of inflammatory bowel disease patients |
| NZ787680A (en) | 2019-10-24 | 2026-02-27 | Cedars Sinai Medical Center | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| US20220409702A1 (en) * | 2019-11-22 | 2022-12-29 | The Research Foundation For The State University Of New York | Compositions and methods for use in type 1 diabetes |
| CN119256009A (zh) * | 2022-06-17 | 2025-01-03 | 塞莱克辛有限公司 | 与人dr3特异性结合的抗体及其用途 |
| AU2024273758A1 (en) | 2023-05-17 | 2025-12-04 | Genentech, Inc. | Anti-tl1a antibody therapeutic methods |
| CN120399074B (zh) * | 2023-06-02 | 2025-12-30 | 安徽金百奥生物科技有限公司 | 一种与人dr3胞外域高亲和力的纳米抗体 |
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
| US20250109209A1 (en) | 2023-10-03 | 2025-04-03 | Absci Corporation | Tl1a associated antibody compositions and methods of use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1989007136A2 (en) | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
| WO1990002806A1 (en) | 1988-09-01 | 1990-03-22 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
| US5162215A (en) | 1988-09-22 | 1992-11-10 | Amgen Inc. | Method of gene transfer into chickens and other avian species |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| AU669367B2 (en) | 1992-04-28 | 1996-06-06 | Yale University | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence |
| ATE183513T1 (de) | 1993-06-03 | 1999-09-15 | Therapeutic Antibodies Inc | Herstellung von antikörperfragmenten |
| US5869248A (en) | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
| US7597886B2 (en) * | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| WO1997018312A1 (en) | 1995-11-14 | 1997-05-22 | Vimrx Holdings, Ltd. | Chimeric oligomers having an rna-cleavage activity |
| KR0161881B1 (ko) | 1995-12-05 | 1999-02-01 | 문정환 | 메모리의 데이타 읽기회로 |
| WO1997033904A1 (en) * | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US5955590A (en) | 1996-07-15 | 1999-09-21 | Worcester Foundation For Biomedical Research | Conjugates of minor groove DNA binders with antisense oligonucleotides |
| US6300483B1 (en) | 1997-06-19 | 2001-10-09 | Ribozyme Pharmaceuticals, Inc. | Compositions inducing cleavage of RNA motifs |
| AU7976198A (en) | 1997-06-19 | 1999-01-04 | Ribozyme Pharmaceuticals, Inc. | Hammerhead ribozymes with extended cleavage rule |
| US7148061B2 (en) | 2000-02-11 | 2006-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| WO2005018571A2 (en) * | 2003-08-20 | 2005-03-03 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
| US20090317388A1 (en) | 2005-05-25 | 2009-12-24 | Linda Burkly | Tl1a in treatment of disease |
| AU2006284922B2 (en) * | 2005-08-30 | 2012-01-19 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins |
| US20110217310A1 (en) | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
| UA104132C2 (en) | 2007-11-13 | 2014-01-10 | Тева Биофармасьютикалз Юесей, Инк. | Humanized antibodies against tl1a |
-
2012
- 2012-03-13 WO PCT/US2012/028926 patent/WO2012161856A1/en not_active Ceased
- 2012-03-13 MX MX2013013329A patent/MX2013013329A/es not_active Application Discontinuation
- 2012-03-13 JP JP2014512833A patent/JP2014518883A/ja not_active Withdrawn
- 2012-03-13 AU AU2012259312A patent/AU2012259312A1/en not_active Abandoned
- 2012-03-13 EP EP12790157.7A patent/EP2709664A4/en not_active Withdrawn
- 2012-03-13 CA CA2836898A patent/CA2836898A1/en not_active Abandoned
- 2012-03-13 US US13/419,203 patent/US9068003B2/en active Active
- 2012-03-13 KR KR1020137033718A patent/KR20140104344A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014518883A5 (enExample) | ||
| JP2018121657A5 (enExample) | ||
| US10358493B2 (en) | Bispecific format suitable for use in high-through-put screening | |
| JP2015214563A5 (enExample) | ||
| JP2017114866A5 (enExample) | ||
| JP2012012402A5 (enExample) | ||
| HRP20151227T1 (hr) | Sastavi i postupci uporabe za terapeutska protutijela | |
| JP2012501669A5 (enExample) | ||
| JP2012501670A5 (enExample) | ||
| CN113226471A (zh) | Il-11ra抗体 | |
| JP2013539369A5 (enExample) | ||
| JP2012143232A5 (enExample) | ||
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| JP2017532005A5 (enExample) | ||
| RU2016123839A (ru) | Новые модуляторы и способы их применения | |
| JP2012520679A5 (enExample) | ||
| JP2020501532A5 (enExample) | ||
| RU2017134909A (ru) | Новая форма IL33, мутировавшие формы IL33, антитела, анализы и способы их применения | |
| JP2018502572A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| JP2016026303A5 (enExample) | ||
| JP2018516853A5 (enExample) | ||
| TWI797124B (zh) | 抗干擾素-γ之抗體及其應用 | |
| JP2010533498A5 (enExample) | ||
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 |